A rare complication of pauci-immune crescentic glomerulonephritis in a child: Questions.
Published in Pediatric nephrology (Berlin, Germany)
A rare complication of pauci-immune crescentic glomerulonephritis in a child: Answers.
Published in Pediatric nephrology (Berlin, Germany)
Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome
Published in Clinical Kidney Journal
Atypical hemolytic uremic syndrome (aHUS) treatment consists of eculizumab. Severe acute respiratory syndrome coronavirus 2 causes severe pneumonia and endothelial injury that leads to a prothrombotic state that may be complicated by macrovascular and microvascular thrombosis. Complement activation is thought to contribute to endothelial injury and...
Autoantibodies in Kidney Diseases
Published in Frontiers in Immunology
Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemia...
Published in Frontiers in Immunology
The complement system alternative pathway (AP) can be activated excessively in inflammatory diseases, particularly when there is defective complement regulation. For instance, deficiency in complement regulators CD55 and CD59, leads to paroxysmal nocturnal hemoglobinuria (PNH), whereas Factor H mutations predispose to atypical hemolytic uremic synd...
Ockham’s razor defeated: about two atypical cases of hemolytic uremic syndrome
...Published in BMC Nephrology
BackgroundMedical investigation is a favorite application of Ockham’s razor, in virtue of which when presented with competing hypotheses, the solution with the fewest assumptions should be privileged. Hemolytic uremic syndrome (HUS) encompasses diseases with distinct pathological mechanisms, such as HUS due to shiga-like toxin-producing bacteria (S...
Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry
...Published in Kidney International Reports
Eculizumab in chemotherapy-induced thrombotic microangiopathy
Published in Clinical Nephrology. Case Studies
Thrombotic microangiopathy (TMA) is a rare but severe complication of tumors and their chemotherapeutic treatment. We report on two patients with chemotherapy-induced TMA who were successfully treated with a short course of the terminal complement inhibitor eculizumab. Both patients quickly achieved remission of microangiopathic hemolytic anemia an...
Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report
Published in Frontiers in Immunology
Preeclampsia is a pregnancy-specific disorder affecting ca 3% of all pregnant women. Preeclampsia is the source of severe pregnancy complications. Later life consequences for mother and infant include increased risk of cardiovascular disease. Preeclampsia is caused by the dysfunction of the endothelium with subsequent activation of complement and c...
Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrom...
Published in CEN Case Reports
Eculizumab, a humanized monoclonal antibody to complement C5, is a therapeutic drug for atypical hemolytic–uremic syndrome (aHUS) that inhibits the terminal pathway of complement. Patients on eculizumab therapy may become more susceptible to infection with capsule-forming bacteria, including meningococci. Therefore, meningococcal vaccination is req...
